Clinical Trial: A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07172867) titled 'A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM' on Aug. 25.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: Diabetes Mellitus, Type 2 Obesity

Intervention: DRUG: HT-6184

2mg QD

DRUG: HT-6184 Matching Placebo

2mg QD

DRUG: Semaglutide 1 mg

Semaglutide 1 mg, every week

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Halia Therapeutics, In...